The phosphorylated membrane Estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer

Cancer

Volumn 113, Issue 6, 2008, Pages 1489-1495

  Mintz, Paul J ^a   Habib, Nagy A ^a   Jones, J Louise ^b   Giamas, Georgios ^a   Lewis, Jacqueline S ^c   Bowen, Rebecca L ^b   Coombes, R Charles ^a   Stebbing, Justin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Barts   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Breast cancer; Estrogen receptor; Fresh tissue; Membrane

Indexed keywords

BCL 2 AGONIST OF DEATH PROTEIN; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOGENESIS; CARCINOMA IN SITU; CELL MEMBRANE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PHOSPHORYLATION; PRIORITY JOURNAL; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL MEMBRANE; CYTOPLASM; CYTOSOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; IMMUNOPRECIPITATION; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 53149134659     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23699     Document Type: Article

References (37)

1. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by 2 distinct signal transduction pathways revealed by phosphorylationspecific antisera. Oncogene. 2002;21:4921-4931.
2. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell. 2004;5:597-605.
3. Wang I.H. Yang XY, Zhang X, et al. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006;10:487-499.
4. Rajah I.D, Hamdan MA. Early childhood caries and risk factors in Jordan. Community Dent Health. 2002;19:224-229.
5. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905-931.
6. Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasm. 2000;5:271-281.
7. Pietras RJ, Levin ER, Szego CM. Estrogen receptors and cell signaling. Science 2005;310:51-53; author reply 51-53.
8. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer. 2007;7: 46-53.
9. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst. 2007;99:350-356.
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001;(1);CD000486.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
12. Pietras RJ, Szego CM. Endometrial cell calcium and oestrogen action. Nature. 1975;253:357-359.
13. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977;265:69-72.
14. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
15. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996-2009.
16. Satoh M, Matter CM, Ogita H, et al. Inhibition of apoptosis-regulated signaling kinase-I and prevention of congestive heart failure by estrogen. Circulation. 2007;115:3197-3204.
17. Forster C, Kietz S, Hultenby K, Warner M, Gustafsson JA. Characterization of the ERbeta-/-mouse heart. Proc Natl Acad Sci U S A. 2004;101:14234-14239.
18. He J, Kargacin ME, Kargacin GJ, Ward CA. Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2003;285:H661-H668.
19. Zhao L, Brinton RD. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2 +) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res. 2007:1172:48-59.
20. Ye B, Zhang Y, Song W, Younger SH, Jan LY, Jan YN. Growing dendrites and axons differ in their reliance on the secretory pathway. Cell. 2007;130:717-729.
21. Metivier R, Penot G. Hubner MR, et al. Estrogen receptoralpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003; 115:751-763.
22. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasomemediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell. 2003;11:695-707.
23. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643-658.
24. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem. 1981;256:1604-1607.
25. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008, 108: 351-361.
26. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004;18:2854-2865.
27. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem. 2007;282: 22278-22288.
28. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307-319.
29. Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol. 2002; 16:116-127.
30. Yang E, Zha J, Jockel I, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80: 285-291.
31. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-1337.
32. Fernando RI, Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell. 2004; 15:3266-3284.
33. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000;60:5988-5994.
34. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996;15:1292-1300.
35. Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol. 1999;58:425-430.
36. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207-212.
37. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular+ estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630.